Chronic-Lymphocytic-Leukemia
December 7, 2023
Chronic lymphocytic leukemia (CLL) is a slow-growing blood cancer involving the abnormal overgrowth of
a type of white blood cell called B-lymphocytes.
Chronic lymphocytic leukemia (CLL) is a slow-growing blood cancer involving the abnormal overgrowth of
a type of white blood cell called B-lymphocytes.
Autoimmune hemolytic anemia (AIHA) is the most common autoimmune condition associated with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Tumor lysis syndrome is a rare condition that can happen due to the rapid death of cancer cells. When the cancer cells are killed, the debris from inside the cells enters the bloodstream.
Education On-Demand Education On-Demand The varied educational activities offered by CLL Society are your opportunities to learn basic information, dive deep into specific topics, or stay abreast of cutting-edge news and
August 2025 marks two full years that I’ve enjoyed the benefits from my trial of epcoritamab, a bispecific T-cell-engaging monoclonal antibody for my CLL. But the last remains of my chronic lymphocytic leukemia (CLL) have remained stubbornly persistent for about a year and a half.
An ongoing phase 2 clinical trial is testing whether adding venetoclax to first-line BTK inhibitor therapy can deepen remissions for CLL patients.
MRD guided venetoclax based therapy can lead to durable remissions in both the frontline and relapsed/refractory (R/R) setting in CLL
Treatment with ibrutinib-venetoclax produced high rates of uMRD and durable progression-free survival in patients with CLL irrespective of lymph node size.
Atezolizumab-venetoclax-obinutuzumab produced high remission rates, but immune-related side effects limit its usefulness as a frontline CLL therapy.